Sign in

    Adam Evertts

    Research Analyst at LifeSci Capital

    Adam Evertts, Ph.D., is the Managing Director and Director of Research at LifeSci Capital, specializing in life sciences sector equity analysis with a focus on biopharmaceutical and healthcare companies. He has directly covered firms such as MEI Pharma and Oramed Pharmaceuticals, contributing targeted research and strategic investment insights, though specific published performance metrics are not publicly available. Evertts began his career in private equity and venture capital before joining LifeSci Advisors and later rising to lead research at LifeSci Capital, demonstrating a deep expertise in drug development and biomedical innovation across multiple industry roles. He holds a Ph.D. and occupies FINRA-registered capacities through LifeSci Capital, and is recognized for providing high-impact support in strategic financial decision-making for institutional clients.

    Adam Evertts's questions to Lite Strategy (MEIP) leadership

    Adam Evertts's questions to Lite Strategy (MEIP) leadership • Q4 2021

    Question

    Adam Evertts from LifeSci Capital pressed for clarity on what specific safety data, such as discontinuation rates, might be shared in the TIDAL readout. He also asked about the planned dosing strategy for zandelisib in the CLL combination trial with venetoclax and rituximab.

    Answer

    Dan Gold, President and CEO, acknowledged the importance of safety metrics but could not promise specific details like discontinuation rates in the top-line release, prioritizing the release of 100% clean and validated data first. For the CLL trial, he confirmed the plan is to follow the Murano regimen for venetoclax/rituximab and administer zandelisib for a fixed duration.

    Ask Fintool Equity Research AI

    Adam Evertts's questions to Lite Strategy (MEIP) leadership • Q4 2020

    Question

    Adam Evertts from LifeSci Capital inquired about the planned marginal zone lymphoma cohort, asking for specifics on the expected number of patients and the potential enrollment timeline.

    Answer

    President and CEO Dan Gold responded that the company is contemplating enrolling approximately 60 patients in the marginal zone lymphoma cohort amendment. He stated that it was premature to provide a specific enrollment timeline, as they first need to gauge interest and capacity from the global clinical sites, noting that these patients can be less common than those with follicular lymphoma.

    Ask Fintool Equity Research AI